For laboratory research use only. Not for human consumption.
Talk to our research support team: 512-998-2437
For laboratory research use only. Not for human consumption.
Talk to our research support team: 512-998-2437
Price range: $133.00 through $1,260.00
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
Research Use Only
All research peptides supplied by OPTMZ Peptides are intended strictly for laboratory research applications and are not designed for medical use. These materials are not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. By purchasing, the buyer confirms use strictly for scientific research purposes and not for human or animal consumption.
Product Overview
KLOW is a four-component research formulation combining BPC-157, GHK-Cu, TB-500, and KPV in a single lyophilized preparation.
The individual components are investigated across distinct areas of experimental biology. BPC-157 is a 15-amino-acid peptide used in cellular and signaling research. GHK-Cu is a copper-binding tripeptide studied in fibroblast and extracellular-matrix biology. TB-500 is an acetylated seven-amino-acid thymosin β4 fragment, while KPV is the Lys-Pro-Val tripeptide corresponding to the C-terminal sequence of α-MSH.
Independent HPLC-UV-MS analysis of the current OPTMZ Peptides sample confirmed the identity of all four analytes.
BPC-157
PubChem reports BPC-157 with formula C₆₂H₉₈N₁₆O₂₂ and molecular weight 1419.5 g/mol.
GHK-Cu
GHK-Cu is a copper complex of the Gly-His-Lys tripeptide. PubChem maintains multiple copper-GHK structural records depending on coordination/speciation, including records with molecular weights of approximately 400.90 and 744.3 g/mol. For this reason, the exact molecular formula should be tied to the specific copper complex supplied rather than assumed from the product name alone.
KPV
The CAS and analytical values above are reported directly by the laboratory for this KLOW sample.
TB-500
FDA identifies TB-500 free base as the acetylated seven-amino-acid thymosin β4 fragment associated with CAS 885340-08-9.
Each tested batch of KLOW undergoes analytical evaluation to verify chromatographic purity, component identity, individual compound content, and analytical consistency.
For the submitted OPTMZ Peptides sample, Krause Analytical reported:
The laboratory specifies that reported values are on a per-vial basis unless otherwise noted.
The COA also includes the chromatogram for sample 205075 on page 2 and its mass-spectral report on page 3.
KLOW should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability, copper-complex integrity, and analytical consistency.
Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation and storage should follow validated laboratory procedures appropriate to the intended research system.
The four KLOW components are investigated individually across several areas of experimental biology.
Research involving BPC-157 includes cellular signaling, endothelial biology, vascular-associated pathways, and peptide structure-function studies.
Research involving GHK-Cu includes copper-peptide chemistry, fibroblast biology, extracellular-matrix regulation, and collagen-associated research. PubChem identifies GHK-Cu as a copper complex of the Gly-His-Lys tripeptide.
Research involving TB-500 includes thymosin β4 fragment biology and actin-associated experimental pathways. FDA identifies TB-500 as thymosin β4 fragment LKKTETQ and notes limited human-exposure information for the compound.
Research involving KPV includes tripeptide biology and experimental inflammatory-signaling models.
These individual research contexts do not establish efficacy or synergy for the four-component KLOW formulation.
KLOW provides four analytically identifiable research compounds in one formulation and may be relevant to controlled experiments involving:
The current COA verifies component identity and content; it does not establish that combining the four compounds produces additive or synergistic biological activity.
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
All products currently listed on this site are for research purposes ONLY.
BPC-157
PubChem reports BPC-157 with formula C₆₂H₉₈N₁₆O₂₂ and molecular weight 1419.5 g/mol.
GHK-Cu
GHK-Cu is a copper complex of the Gly-His-Lys tripeptide. PubChem maintains multiple copper-GHK structural records depending on coordination/speciation, including records with molecular weights of approximately 400.90 and 744.3 g/mol. For this reason, the exact molecular formula should be tied to the specific copper complex supplied rather than assumed from the product name alone.
KPV
The CAS and analytical values above are reported directly by the laboratory for this KLOW sample.
TB-500
FDA identifies TB-500 free base as the acetylated seven-amino-acid thymosin β4 fragment associated with CAS 885340-08-9.
Each tested batch of KLOW undergoes analytical evaluation to verify chromatographic purity, component identity, individual compound content, and analytical consistency.
For the submitted OPTMZ Peptides sample, Krause Analytical reported:
The laboratory specifies that reported values are on a per-vial basis unless otherwise noted.
The COA also includes the chromatogram for sample 205075 on page 2 and its mass-spectral report on page 3.
KLOW should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability, copper-complex integrity, and analytical consistency.
Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation and storage should follow validated laboratory procedures appropriate to the intended research system.
The four KLOW components are investigated individually across several areas of experimental biology.
Research involving BPC-157 includes cellular signaling, endothelial biology, vascular-associated pathways, and peptide structure-function studies.
Research involving GHK-Cu includes copper-peptide chemistry, fibroblast biology, extracellular-matrix regulation, and collagen-associated research. PubChem identifies GHK-Cu as a copper complex of the Gly-His-Lys tripeptide.
Research involving TB-500 includes thymosin β4 fragment biology and actin-associated experimental pathways. FDA identifies TB-500 as thymosin β4 fragment LKKTETQ and notes limited human-exposure information for the compound.
Research involving KPV includes tripeptide biology and experimental inflammatory-signaling models.
These individual research contexts do not establish efficacy or synergy for the four-component KLOW formulation.
KLOW provides four analytically identifiable research compounds in one formulation and may be relevant to controlled experiments involving:
The current COA verifies component identity and content; it does not establish that combining the four compounds produces additive or synergistic biological activity.
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
All products currently listed on this site are for research purposes ONLY.
| Pcs | Single Vial, Pack of 10 |
|---|
Quad Research Peptide Blend / Multi-Peptide Research Formulation
Cell Biology; Peptide Biology; Molecular Signaling; Vascular Biology; Fibroblast Biology; Extracellular-Matrix Biology; Copper-Peptide Research; Immunology
Multiple experimental pathways; no single shared molecular target Relevant research contexts include: BPC-157: Cellular and vascular-associated signaling GHK-Cu: Copper-associated signaling, fibroblast and extracellular-matrix pathways TB-500: Thymosin β4 fragment / actin-associated research KPV: Inflammatory-signaling and peptide-transport research The four-component formulation itself does not have an established unified molecular target.
Preclinical Research Research relevant to these compounds consists predominantly of biochemical, cellular, animal, and other preclinical investigations. Evidence for the combined KLOW formulation is substantially more limited than research involving the individual constituents.
KLOW contains four structurally distinct peptide-based research compounds: BPC-157, a 15-amino-acid peptide; GHK-Cu, a copper-associated Gly-His-Lys tripeptide complex; TB-500, an N-terminally acetylated seven-amino-acid thymosin β4 fragment; and KPV, the Lys-Pro-Val tripeptide. Independent HPLC-UV-MS analysis confirmed the identity of all four analytes in the tested sample.
BPC-157: GEPPPGKPADDAGLV GHK-Cu: Gly-His-Lys GHK TB-500: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln Ac-LKKTETQ KPV: Lys-Pro-Val KPV FDA specifically identifies the TB-500 fragment as LKKTETQ.
Peptide signaling research
Fibroblast biology
Extracellular-matrix studies
Copper-peptide research
Cellular migration models
Endothelial-cell research
Vascular biology
Cytoskeletal-associated research
Inflammatory-signaling research
Peptide transport studies
Peptide structure-function analysis
Multi-peptide analytical research
xperimental systems relevant to research involving the individual constituents include:
Fibroblast cell-culture systems
Endothelial-cell models
Extracellular-matrix experimental systems
Copper-peptide biochemical models
Cellular migration systems
Peptide transport systems
Immune-cell models
Intestinal epithelial-cell models
Cytoskeletal and actin-associated systems
Preclinical tissue-response models
These systems apply to research involving individual components and should not be represented as validation of the combined KLOW formulation.
HPLC-UV purity analysis
LC-MS identity analysis
Mass-spectral matching
USP endotoxin testing
Fibroblast proliferation assays
Collagen and extracellular-matrix assays
Cell-migration assays
Endothelial-cell assays
Peptide-transport assays
Inflammatory-signaling assays
Cytoskeletal analysis
Peptide stability and metabolism assays
For the actual OPTMZ lot, the COA specifically documents HPLC-UV-MS analysis and USP endotoxin testing.
Chromatographic purity
Individual component identity
Individual peptide content
Endotoxin concentration
Cellular migration
Fibroblast responses
Extracellular-matrix activity
Endothelial-cell responses
Peptide transport
Inflammatory-signaling markers
Cytoskeletal-associated responses
Copper-peptide interactions
For the tested KLOW product itself, the directly measured analytical endpoints were purity, identity, individual analyte quantity, and endotoxin concentration.
Independent analytical testing of OPTMZ Peptides KLOW, nominally 80 mg total, batch/lot 2026/02, by Krause Analytical reported:
Chromatographic Purity: 99.4%
BPC-157 Content: 9.20 mg
BPC-157 Label Claim: 10 mg
BPC-157 Percent of Label: 92.0%
BPC-157 Identity: Confirmed
GHK-Cu Content: 32.5 mg
GHK-Cu Label Claim: 50 mg
GHK-Cu Percent of Label: 65.0%
GHK-Cu Identity: Confirmed
KPV Content: 6.32 mg
KPV Label Claim: 10 mg
KPV Percent of Label: 63.2%
KPV Identity: Confirmed
TB-500 Content: 14.7 mg
TB-500 Label Claim: 10 mg
TB-500 Percent of Label: 147.0%
TB-500 Identity: Confirmed
Total Measured Analyte Content: 62.72 mg
Analysis Method: HPLC-UV-MS
Endotoxins: <0.5 EU/mL
Endotoxin Method: USP
Lab Number: 205075
Project: 145211
Report Issued: May 19, 2026
The laboratory reports all values on a per-vial basis unless otherwise noted.
Restricted Access · Research Use Only
Independently lab tested, every batch
COAs published and searchable by batch number
Policy version 2026-05-14-ruo-v1.0
Reviews
There are no reviews yet.